ASCRS 2024: Ultra-low cylinder powered toric versus non-toric lenses in cataract surgery

News
Video

Adam Muzychuk, MD, BSc, FRCSC, discusses his ASCRS 2024 presentation on toric lens use for patients with low astigmatism

At this year's ASCRS meeting in Boston, Massachusetts, we spoke with Adam Muzychuk, MD, BSc, FRCSC. He told Ophthalmology Times Europe about his presentation, titled "Outcomes of an ultra-low cylinder powered (0.90) toric versus non-toric in low astigmatic patients undergoing cataract surgery." In this video, he provides highlights from the lecture.

Editor's note: The below transcript has been lightly edited for clarity

I'm Adam Muzychuk. I'm fellowship-trained in cornea and external disease. I practice in private practice in Calgary, Alberta and I have university affiliation with the University of Calgary. I'm here today to talk about outcomes of a an ultra-low cylinder power toric IOL versus a non-toric control. A large study in 2021 demonstrated that 0.5 diopters or more of refractive astigmatism is visually significant.

This is a landmark paper that said that we should be maximally treating all refractive cylinder where we can. What's not known is, even if we should treat it, how accurately are we able to, and can we do it with the equipment that we already have in our office? We utilize the IOLMaster 500 [ZEISS Meditec] along with the Storz Bubble Marker [Bausch + Lomb], which, in other words, is very basic equipment that is available essentially to any surgeon who's deploying toric lenses. In terms of outcomes of the study, patients who underwent implantation with the 0.90 toric had a significantly greater reduction in astigmatism postoperatively, almost three times as many eyes had plano cylinder outcomes, twice as many had outcomes within a quarter diopter, and 92.2% of eyes with the 0.90 toric were within a half a diopter of plano cylinder.

The importance of this study is there are still regulatory regions, such as the United States, where 0.90 diopter torics do not exist due to regulatory requirements that have not yet passed, as well as 1.0 diopters. The importance of this is that these lenses work. They're highly effective in reducing visually significant postoperative cylinder, where maximal correction is shown to have important effects for vision. Where [these lenses are] approved, we have better visual performance for patients, fewer laser enhancements, and overall more satisfied patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.